Episode Twelve: AI’s Real-World Impact on Pharma & What’s Next in 2025
Join us for the next episode of AI Uncovered featuring Emmanuel Walckenaer, CEO of Yseop, back to AI Uncovered for a follow-up conversation on the rapid evolution of AI in biopharma. Since his last appearance, the industry has made significant strides in harnessing AI for regulatory submissions, clinical workflows, and medical writing—areas where Yseop is leading the charge in transforming content generation.
In this episode, Tim and Emmanuel revisit the biggest AI breakthroughs of 2024 and explore how the pharmaceutical sector is shifting from skepticism to large-scale adoption. They discuss real-world success stories, the growing impact of federated data sharing, and what companies should prioritize as they plan for 2025 and beyond.
With his unique perspective on SaaS growth, AI regulation, and enterprise adoption, Emmanuel provides invaluable insights for professionals navigating the intersection of AI and life sciences. If you’re looking to understand the next wave of AI-driven innovation in pharma, this is an episode you won’t want to miss.
“Some customers have already announced that they gained two weeks and are targeting to gain an additional five weeks in this overall process…”
Listen and subscribe to AI Uncovered on all major podcast platforms:
About AI Uncovered
AI Uncovered is our podcast, made for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.
With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization.
Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.
The post AI Uncovered with Emmanuel Walckenaer (AI’s Real-World Impact on Pharma & What’s Next in 2025) appeared first on Yseop.
